Introducing Lonza’s New Developability Assessment Platform
Lonza now provides a complete Developability Assessment Toolbox that consists of a suite of in silico tools and protein structure expertise. The Platform includes Manufacturability and Safety Assessment Services applicable to customers in both discovery and early stage biological drug development.
- Manufacturability Assessment Service analyzes chemical degradation pathways and post translational modifications including deamidation, oxidation and glycosylation, as well as potential physical stability issues, most notably, protein aggregation.
- Safety Assessment Service uses our proprietary Epibase™ In silico Screening tool to identify T-cell epitopes in target proteins that may trigger potential immune reactions in human studies.
The Benefits of Early Risk Assessment Include:
- Reduction in development costs and time
- Acceleration of the lead candidate selection process
- Increase the chance of a candidates success
- Potential optimization of the process before problems arise in development
- Improved chance of successful manufacturing scale-up
The post assessment deliverables include full reports highlighting the predictions and analyses from the services listed above. If high-risk issues are identified in the initial assessment, our experts have an extensive range of protein engineering capabilities that have the potential to improve the structure, biological activity and the manufacturing properties of your drug candidate.
To learn more about Lonza's Developability Services, dowload our webinar entitled: "Developability: Reducing the Risk of Failure of Biotherapeutic Candidates" given by Noel Smith, Ph.D., Senior Scientist, Lonza Applied Protein Services.
To learn more about a therapeutic protein's journey through the immune pathway, watch our
Immunogenicity Services video.